Independent directory Public ClinicalTrials.gov records United States
Sponsor Directory

Dana-Farber Cancer Institute clinical trials

Sponsor pages show live ClinicalTrials.gov search results and objective aggregate stats only. They do not describe sponsor quality, reputation, or expected outcomes.

ClinicalTrials.gov public records Last synced Nov 20, 2026, 5:11 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
1270
Shown on this page
12
Local recruiting
103
Top conditions
6

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this sponsor

These controls apply only within Dana-Farber Cancer Institute. Default order is Recently updated. Add condition, therapy, location, or recruitment status to narrow this sponsor page further.

Reset sponsor filters
Clear filters
Showing 1–12 of 1,270 matching trials for sponsor Dana-Farber Cancer Institute.
Live ClinicalTrials.gov results.

Live official records

Open in full search
Completed Phase 2 Interventional Results available

Cisplatin vs. Doxorubicin/Cyclophosphamide in BrCa

NCT01670500
Conditions
Breast Cancer
Interventions
Cisplatin, Cyclophosphamide, Doxorubicin
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2025
U.S. locations
15
States / cities
Aurora, Colorado • Derby, Connecticut • Guilford, Connecticut + 9 more
Recruiting Not applicable Interventional

Neurocognitive Assessment CNSL and LGG

NCT07710131
Conditions
PCNSL, Brain Tumor, Cognitive Dysfunction, IDH Mutation, Low-grade Glioma
Interventions
Digital Cognitive Assessment (TestMyBrain and Mobile Toolbox), Traditional Neuropsychological Testing, Quality of Life and Mood Questionnaires, Brain MRI (Standard of Care)
Behavioral · Other
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Prostate Cancer
Interventions
Apalutamide, Abiraterone Acetate, Prednisone, GnRH agonist/antagonist
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
11
States / cities
Chicago, Illinois • Evanston, Illinois • Boston, Massachusetts + 8 more
Active, not recruiting Phase 1 Interventional

IS-free Treg HaploHCT

NCT04678401
Conditions
Stem Cell Transplant Complications, Graft Vs Host Disease, Myeloid Leukemia, Acute, Myeloid Leukemia in Relapse (Disorder), Myelodysplastic Syndromes
Interventions
Radiation, Fludarabine, Thiotepa, Cyclophosphamide, Mesna, Treg-enriched donor cell, Unmodified donor T Cell, CD34+ Haplo Peripheral Blood Stem Cell, Melphalan
Radiation · Drug · Biological + 1 more
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Multiple Myeloma
Interventions
Bortezomib, Lenalidomide, Dexamethasone, Stem Cell Mobilization, Autologous Stem Cell Transplant
Drug · Procedure
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2025
U.S. locations
8
States / cities
Denver, Colorado • Brewer, Maine • Boston, Massachusetts + 3 more
Active, not recruiting Phase 1 Interventional Results available

Phase Ia/Ib Talazoparib + Tazemetostat for mCRPC

NCT04846478
Conditions
Metastatic Prostate Cancer, Metastatic Castration-resistant Prostate Cancer
Interventions
Talazoparib, Tazemetostat
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
2
States / cities
Boston, Massachusetts
Conditions
Relapsed or Refractory Acute Myeloid Leukemia (AML)
Interventions
Dynamic BH3 Profiling, Venetoclax, Cytarabine, Gilteritinib, Azacitidine (AZA), Tagraxofusp, Decitabine, Revumenib, Cladribine (CLAD)
Device · Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2030
U.S. locations
2
States / cities
Boston, Massachusetts
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

The DISCOVER Study

NCT07390643
Conditions
Cancer, Cancer Diagnosis
Interventions
GRAIL Galleri MCED test
Device
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
22 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Ovarian Cancer, Ovarian Carcinoma, Endometrial Cancer, Uterine Cancer, Cervical Cancer, Vulvar Cancer, Gynecologic Cancer, Vaginal Cancer
Interventions
Belzutifan
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
2
States / cities
Boston, Massachusetts
Conditions
Melanoma Stage III, Melanoma Stage IV
Interventions
SX-682, Pembrolizumab
Drug · Biological
Lead sponsor
Syntrix Biosystems, Inc.
Industry
Eligibility
18 Years and older
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
6
States / cities
Miami, Florida • Boston, Massachusetts • Rochester, Minnesota + 2 more
Conditions
B-cell Acute Lymphoblastic Leukemia, Chronic Myeloid Leukemia (CML) in Lymphoid Blast Crisis, Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Ph+ ALL
Interventions
ABL001, Dasatinib, Prednisone, Blinatumomab
Drug
Lead sponsor
Marlise Luskin, MD
Other
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
4
States / cities
Chicago, Illinois • Boston, Massachusetts • Buffalo, New York
Conditions
Myelodysplastic Syndromes, de Novo, Myelodysplastic Syndromes, Secondary, Myelodysplastic Syndromes, Previously Treated, Treatment-Related Acute Myeloid Leukemia, Therapy-Related Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia With Failed Remission, Lymphoblastic Lymphoma, in Relapse, Lymphoblastic Lymphoma, Refractory, Acute Leukemia of Ambiguous Lineage in Relapse, Acute Leukemia of Ambiguous Lineage
Interventions
Venetoclax, Azacitidine, Cytarabine, Methotrexate, Hydrocortisone, Leucovorin, Dexamethasone, Vincristine, Doxorubicin, Dexrazoxane, Calaspargase Pegol, Erwinia asparaginase
Drug
Lead sponsor
Andrew E. Place, MD
Other
Eligibility
1 Year to 40 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
5
States / cities
San Francisco, California • Aurora, Colorado • Atlanta, Georgia + 2 more

About this Dana-Farber Cancer Institute sponsor directory page

What this page lists
U.S. ClinicalTrials.gov public records where Dana-Farber Cancer Institute is the lead sponsor, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
How to narrow results
Use the filters above to scope by condition, intervention, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Dana-Farber Cancer Institute trials.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, sponsor quality scoring, ranking of trials, or AI-generated medical summaries.

Related: all sponsor pages, browse by condition, browse by drug or therapy, browse by U.S. city, trials at Dana-Farber Cancer Institute in Boston, MA, or open the full search for Dana-Farber Cancer Institute.